Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism

Thrombosis and Haemostasis

Volumn 107, Issue 1, 2012, Pages 37-43

  Marchena, Pablo Javier ^a   Nieto, José Antonio ^b   Guil, María ^c   García Bragado, Ferrán ^d   Rabuñal, Ramón ^e   Boccalon, Henri ^f   Trujillo Santos, Javier ^g   Monreal, Manuel ^h  

^a PARC SANITARI SANT JOAN DE DÉU   (Spain)

^b HOSPITAL VIRGEN DE LA LUZ   (Spain)

^c Especialidad en Oftalmología Hospital Comarcal de la Axarquía Vélez Málaga Málaga   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e Servicio de Medicina Interna   (Spain)

^f CHU RANGUEIL   (France)

^g Allergy Section   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cancer; Heparins; Pulmonary embolism; Venous thrombosis

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN CANCER; BREAST CANCER; CANCER PATIENT; DIGESTIVE SYSTEM CANCER; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; LONG TERM CARE; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RECURRENT DISEASE; REGISTER; SCORING SYSTEM; UROGENITAL TRACT CANCER; VENOUS THROMBOEMBOLISM;

AGED; ALGORITHMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PULMONARY EMBOLISM; RECURRENCE; REGISTRIES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84855338225     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-06-0423     Document Type: Article

References (24)

1. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002; 162: 1729-1735
2. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weigh heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 34: 146-153
3. Deitcher SR, Kessler CM, Merli G, et al., for the ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Haemost 2006; 12: 389-396
4. Hull RD, Pineo GF, Brant RF. et al.; LITE Trial investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119: 1062-1072
5. Kearon C, Kahn SR, Agnelli G, et al.; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133: 454S-545S.
6. Wagman LD, Baird MF, Bennett CL, et al. National Comprehensive Cancer Network. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2008; 6: 716-753
7. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505
8. Debourdeau P, Kassab Chahmi D, et al. 2008 SOR* French guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: Report from the working group. Ann Oncol 2009; 20: 1459-1471
9. Farge D, Kassab-Chahmi D, Bosquet L, et al. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group. Crit Rev Oncol Hematol 2010; 73: 31-46
10. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27: 4919-4926
11. Monreal M, Falgá C, Valdés M, et al; for the RIETE Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: Findings from the RIETE Registry. J Thromb Haemost 2006; 4: 1950-1956
12. Laporte S, Mismetti P, Découssus H, et al., RIETE investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism; Findings from the registro informatizado de la enfermedad tromboembólica venosa (RIETE) Registry. Circulation 2008; 117: 1711-1716
13. Trujillo-Santos, Nieto JA, Tiberio G, et al., RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 435-439
14. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197
15. Das SK, Cohen AT, Edmonson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-527
16. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81: 26-31
17. Gonzalez-Fajardo J, Arreba W, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep vein thrombosis. J Vasc Surg 1999; 30: 283-292
18. Veiga F, Escriba A, Maluenda M, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep vein thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84: 559-564
19. Lopez-Beret P, Orgaz A, Fontcuberta J, et al. Low-molecular weight heparin versus oral anticoagulant in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33: 77-90
20. Hull R, Pineo G, Mah AF. The LITE Investigators. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2000; 96: 1933 (Abstract).
21. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1: 1906-1913
22. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281
23. Ruíz-Giménez N, Suárez C, González R, et al., RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 26-31
24. Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism. Findings from the RIETE Registry. J Thromb Haemost 2010; 8: 1216-1222.